Real-time financial, economic, and global news with market-focused context and analysis.
Coverage spans equities, macroeconomic data, commodities, currencies, technology, politics, and global events—paired with analysis that highlights why each development matters for traders and investors. From breaking headlines to hourly market snapshots and in-depth articles, the News Hub is designed to help you stay informed, oriented, and ahead of market-moving events.
USA Rare Earth, a Nasdaq-listed company focused on rare earth metals and permanent magnets, announced it will release its financial results for Q2 2026 on August 10, followed by a conference call to discuss outcomes and operational progress. The company is advancing its integrated supply chain spanning mining, metal production, and magnet manufactu…
Fiserv, Inc. reported its second quarter 2026 financial results showing a 4% decrease in GAAP revenue and 37% decline in GAAP earnings per share compared to the prior year. Both Merchant Solutions and Financial Solutions segments experienced revenue declines. The company also updated its 2026 organic revenue outlook to a range of -1% to 0% and adju…
Datadog announced its second quarter 2026 financial results with $1.12 billion in revenue, representing 36% year-over-year growth. The company reported positive free cash flow of $279 million and maintained a solid customer base expansion, with approximately 4,720 customers generating over $100k ARR, up 23% from the prior year. Datadog also launche…
Climb Bio, Inc., a clinical-stage biotechnology company focused on immune-mediated diseases, reported its second quarter 2026 financial results and provided updates on key clinical programs. The company highlighted progress in its CLYM116 and budoprutug trials, including upcoming Phase 1 and 2 data presentations and ongoing enrollment. A $110 milli…
Lantheus Holdings, a US-listed radiopharmaceutical company, reported second quarter 2026 revenue of $388.2 million, up 2.7% year-over-year, with adjusted earnings per share slightly down to $1.55. The company announced a definitive agreement for an $8.0 billion all-cash merger with Curium US Holdings LLC, valuing Lantheus shares at $102.50 per shar…
KVH Industries reported a 27% increase in total revenues for Q2 2026 compared to the same quarter last year, driven by a substantial rise in low earth orbit (LEO) service sales primarily from Starlink and OneWeb subscribers. Service revenues grew significantly while product sales saw an 11-12% increase. The company highlights strategic progress in …
Sotera Health Company delivered strong financial performance in Q2 and the first half of 2026, with double-digit increases in net income and Adjusted EBITDA margins. The company raised its full-year 2026 revenue and Adjusted EBITDA growth outlook, driven by solid growth across its three business segments: Sterigenics, Nordion, and Nelson Labs. Impr…
Intellia Therapeutics announced promising Phase 3 clinical trial results for lonvoguran ziclumeran (lonvo-z), an in vivo CRISPR gene editing candidate for hereditary angioedema (HAE), demonstrating significant attack reduction and favorable safety profile. The company expects FDA acceptance of a biologics license application (BLA) in the second hal…
American Shared Hospital Services announced its upcoming Q2 2026 financial results conference call, highlighting continued growth and expansion in stereotactic radiosurgery, Gamma Knife, proton therapy, and advanced radiation cancer treatments. The company collaborates with health systems to share in capital investment and profitability while focus…
Foghorn Therapeutics provided its Q2 2026 update highlighting progress in its clinical-stage programs, including the Phase 1 dose escalation of FHD-909 targeting SMARCA4-mutant NSCLC, advancement of selective EP300 and CBP degrader programs for hematological malignancies and breast cancer, and initiation of a novel oral immunology inflammation prog…
Peloton Interactive, Inc. announced its Q4 and full fiscal year 2026 financial results, highlighting its first full year of GAAP net profitability with net income of $63 million and an Adjusted EBITDA of $468 million, a 16% year-over-year increase. Total revenue reached $2.446 billion, slightly above guidance, driven by strong equipment sales. The …
Cartesian Therapeutics reported Q2 2026 financial results and business updates highlighting progress in its CAR-T cell therapy pipeline targeting autoimmune diseases including myasthenia gravis, myositis, and juvenile dermatomyositis. The company secured a strategic licensing agreement with WestGene to develop an in vivo CAR-T platform, expects mul…
Immunovant, a clinical-stage immunology company, announced its financial results for the quarter ended June 30, 2026, highlighting a cash position sufficient to support the potential launch of IMVT-1402 in Graves’ disease. The company reported increased R&D expenses reflecting advancement in clinical trials across six indications including Graves’ …
Korro Bio announced its Q2 2026 financial results, highlighting progress in its OPERA platform technology with the upcoming first-in-human trial for KRRO-121 in hyperammonemia and orphan drug designation from the EMA. The company also nominated KRRO-111 as a development candidate for Alpha-1 Antitrypsin Deficiency (AATD), demonstrating significant …
Immunocore Holdings plc reported robust second quarter 2026 financial results, highlighted by 18% year-over-year growth in net revenues for KIMMTRAK reaching $115.9 million. The company is advancing multiple Phase 3 clinical trials, including the TEBE-AM trial for advanced cutaneous melanoma and the PRISM-MEL-301 trial for first-line melanoma, with…
Roivant Sciences reported Q1 FY2027 financial results and provided an update on key pipeline developments. The company is preparing for the commercial launch of brepocitinib for dermatomyositis by September 2026 and expects topline data later this year for several late-stage trials including non-infectious uveitis, cutaneous sarcoidosis, and pulmon…
Priovant Therapeutics has commenced patient enrollment in the global Phase 3 BEACON+ trial evaluating brepocitinib for cutaneous sarcoidosis (CS), following positive Phase 2 results and FDA Breakthrough Therapy Designation. The drug is also progressing in multiple orphan disease indications including dermatomyositis, non-infectious uveitis, and lic…
Aya Gold & Silver Inc. announced the acquisition of a significant exploration portfolio in Morocco, adding 259 km² of land across three projects (Zagora, Agadir-Melloul, and Goulmim). This acquisition increases their total land holdings by 35.4%, strengthens their district-scale exploration strategy, and enhances exposure to precious, base, and cri…
Radian's recent quarter disappointed as newly acquired P&C and specialty lines pressured results, but the balance sheet remains healthy, the stock trades below 10x earnings, and the company's strategic pivot (including the $1.7B Inigo deal) points to upside. This is a tactical long for the mid term (45 trading days) with defined entry, stop and tar…
Shares of major data-storage companies plunged in premarket trading after Sandisk and Western Digital issued quarterly revenue forecasts that topped consensus but disappointed investors holding ambitious AI-era expectations. The declines highlight how quickly market enthusiasm can turn when even robust results fall short of heightened forecasts.
Aclaris Therapeutics released its Q2 2026 financial results, showing increased net loss due to expanded R&D investing in pipeline candidates. The company reaffirmed timelines for pivotal clinical data readouts from multiple Phase 1b and Phase 2 trials targeting immuno-inflammatory diseases such as asthma, atopic dermatitis, and lichen planus. It al…
FIFA’s recent efforts to close ranks around President Gianni Infantino after a contentious proposal to sell part of the World Cup’s commercial future have calmed public acrimony but are unlikely to end scrutiny of the organisation’s governance. FIFA apologised to its 211 member associations for the way the plan was handled, pledged a process review…
Sterling eased slightly while the euro slipped, with both currencies trading cautiously ahead of Friday's U.S. non-farm payrolls report. The dollar remained relatively steady after hawkish comments from Federal Reserve officials, even as an Iran-Oman shipping deal and a drop in Brent crude to below $80 a barrel reduced near-term inflation concerns.
L’Oreal shares climbed after Jefferies raised its recommendation and price target, a move reinforced by the company's record first-half 2026 revenue, robust like-for-like sales growth and a best-ever operating margin. E-commerce expansion and broad division-level growth underpinned investor confidence, while a constructive European macro environmen…
Equity research firm Summit Insights downgraded Western Digital to Hold, pointing to execution and margin risks tied to the company’s move to heat-assisted magnetic recording (HAMR). Analyst Kinngai Chan expects higher costs during the HAMR transition, a forecasted decline in average selling price per exabyte when HAMR drives begin shipping in 2027…
